• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    12/9/24 4:01:23 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care
    Get the next $LNSR alert in real time by email

    ORLANDO, Fla., Dec. 09, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted four newly-hired non-executive employees stock options to purchase an aggregate of 2,475 shares of the Company's common stock. The options were granted as of December 8, 2024, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

    The options have an exercise price of $7.70 per share, which is equal to the closing price of the Company's common stock on the grant date. The options vest as to 25% of the total amount of the award on the one-year anniversary of the vesting commencement date of December 2, 2024 and in thirty-six substantially equal monthly installments thereafter, subject to the new employee's continued service with the company. Each stock option has a 10-year term. The options are subject to the terms and conditions of LENSAR's 2024 Employment Inducement Incentive Award Plan and a stock option agreement covering the grant.

    About LENSAR

    LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. LENSAR has developed its ALLY Robotic Cataract Laser System™ as a compact, highly ergonomic system utilizing an extremely fast dual-modality laser and integrating AI into proprietary imaging and software. ALLY is designed to transform premium cataract surgery by utilizing LENSAR's advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reducing overhead. ALLY includes LENSAR's proprietary Streamline® software technology, which is designed to guide surgeons to achieve better outcomes.

    Contacts: Lee Roth / Cameron Radinovic
    Thomas R. Staab, II, CFO Burns McClellan for LENSAR
    [email protected] [email protected] / [email protected]


    Primary Logo

    Get the next $LNSR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LNSR

    DatePrice TargetRatingAnalyst
    11/22/2021$15.00Buy
    BTIG
    More analyst ratings

    $LNSR
    SEC Filings

    See more
    • SEC Form DEFA14A filed by LENSAR Inc.

      DEFA14A - LENSAR, Inc. (0001320350) (Filer)

      5/22/25 4:47:59 PM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • SEC Form 8-K filed by LENSAR Inc.

      8-K - LENSAR, Inc. (0001320350) (Filer)

      5/22/25 4:43:59 PM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFM14A filed by LENSAR Inc.

      DEFM14A - LENSAR, Inc. (0001320350) (Filer)

      5/19/25 4:31:39 PM ET
      $LNSR
      Medical/Dental Instruments
      Health Care

    $LNSR
    Financials

    Live finance-specific insights

    See more
    • LENSAR Reports First Quarter 2025 Results and Provides Business Update

               14 ALLY Robotic Laser Cataract Systems™ ("ALLY Systems") placed in 1Q 2025 with an additional backlog of 24 systems pending installation as of March 31, 2025 34% Revenue growth over the first quarter 2024 and 22% Recurring revenue growth in the trailing twelve months Worldwide procedure volumes increased 33% over the first quarter of 2024 ORLANDO, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2025 and provided an update on key operational initiatives. "W

      5/8/25 7:00:42 AM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • LENSAR Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

      31 ALLY Robotic Cataract Laser Systems™ placed in Q4 2024, representing an 86% increase in ALLY placements in full year 2024 over 2023; Company's total installed systems increased to approximately 385 as of December 31, 2024, representing a 26% increase over 2023 Fourth quarter 2024 revenue increased 38% over fourth quarter 2023; Full-year revenue increased 27% over 2023 Recurring revenue exceeds $40 million for the full year; increased 23% over 2023 ORLANDO, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financia

      2/27/25 7:00:11 AM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • LENSAR to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 27, 2025

      ORLANDO, Fla., Feb. 19, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company's fourth quarter and full year 2024 financial results will be released before market open on Thursday, February 27, 2025. LENSAR's management will host a conference call and webcast at 8:30 am ET on Thursday, February 27, 2025 to discuss the financial results and recent corporate highlights. To participate by telephone, please use this registration link. All participants must use the link to complete the online registration process in advance

      2/19/25 12:00:25 PM ET
      $LNSR
      Medical/Dental Instruments
      Health Care

    $LNSR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Winer Gary M bought $3,082 worth of shares (685 units at $4.50), increasing direct ownership by 0.85% to 80,840 units (SEC Form 4)

      4 - LENSAR, Inc. (0001320350) (Issuer)

      9/6/24 9:00:13 AM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • Director Winer Gary M bought $10,373 worth of shares (2,302 units at $4.51), increasing direct ownership by 3% to 80,155 units (SEC Form 4)

      4 - LENSAR, Inc. (0001320350) (Issuer)

      8/29/24 6:05:46 AM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • Director Winer Gary M bought $2,185 worth of shares (502 units at $4.35), increasing direct ownership by 0.65% to 77,853 units (SEC Form 4)

      4 - LENSAR, Inc. (0001320350) (Issuer)

      8/23/24 6:52:16 PM ET
      $LNSR
      Medical/Dental Instruments
      Health Care

    $LNSR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • LENSAR Reports First Quarter 2025 Results and Provides Business Update

               14 ALLY Robotic Laser Cataract Systems™ ("ALLY Systems") placed in 1Q 2025 with an additional backlog of 24 systems pending installation as of March 31, 2025 34% Revenue growth over the first quarter 2024 and 22% Recurring revenue growth in the trailing twelve months Worldwide procedure volumes increased 33% over the first quarter of 2024 ORLANDO, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2025 and provided an update on key operational initiatives. "W

      5/8/25 7:00:42 AM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • Alcon Agrees to Acquire LENSAR, Inc.

      Acquisition of ALLY Robotic Cataract Laser Systems strengthens Alcon's cataract equipment and technology portfolioNext generation technology will be expanded globally, improving the efficiency of cataract surgery GENEVA and ORLANDO, Fla., March 24, 2025 (GLOBE NEWSWIRE) -- Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and LENSAR, Inc. (NASDAQ:LNSR), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced the companies have entered into a definitive merger agreement through which Alcon intends to acquire LENSAR. The acquisition includes ALLY Robotic Cataract Laser Treatment Sy

      3/24/25 8:00:00 AM ET
      $ALC
      $LNSR
      Ophthalmic Goods
      Health Care
      Medical/Dental Instruments
    • LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      ORLANDO, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted two newly-hired non-executive employees stock options to purchase an aggregate of 1,600 shares of the Company's common stock. The options were granted as of March 3, 2025, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $13.48 per share, which is equal to the closing price of the Company's common stock on the grant date. The options vest as t

      3/3/25 7:03:12 PM ET
      $LNSR
      Medical/Dental Instruments
      Health Care

    $LNSR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $LNSR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • BTIG initiated coverage on LENSAR with a new price target

      BTIG initiated coverage of LENSAR with a rating of Buy and set a new price target of $15.00

      11/22/21 6:09:40 AM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • SVB Leerink initiated coverage on LENSAR with a new price target

      SVB Leerink initiated coverage of LENSAR with a rating of Outperform and set a new price target of $20.00

      3/2/21 8:10:50 AM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • SVB Leerink initiated coverage on LENSAR with a new price target

      SVB Leerink initiated coverage of LENSAR with a rating of Outperform and set a new price target of $20.00

      2/24/21 6:12:20 AM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by LENSAR Inc.

      SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

      11/14/24 4:05:15 PM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by LENSAR Inc. (Amendment)

      SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

      2/14/24 4:05:39 PM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by LENSAR Inc. (Amendment)

      SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

      2/13/24 4:30:02 PM ET
      $LNSR
      Medical/Dental Instruments
      Health Care

    $LNSR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ellis Thomas B was granted 7,374 shares, increasing direct ownership by 24% to 38,662 units (SEC Form 4)

      4 - LENSAR, Inc. (0001320350) (Issuer)

      5/28/25 4:57:30 PM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • Director Hammer Todd B was granted 7,374 shares, increasing direct ownership by 24% to 38,662 units (SEC Form 4)

      4 - LENSAR, Inc. (0001320350) (Issuer)

      5/28/25 4:56:24 PM ET
      $LNSR
      Medical/Dental Instruments
      Health Care
    • Director Winer Gary M was granted 7,374 shares, increasing direct ownership by 9% to 88,214 units (SEC Form 4)

      4 - LENSAR, Inc. (0001320350) (Issuer)

      5/28/25 4:30:14 PM ET
      $LNSR
      Medical/Dental Instruments
      Health Care